FDA Approves Updated Irrigation Rate for Johnson & Johnson's VARIPULSE Pulsed Field Ablation Platform
核心洞察
Johnson & Johnson MedTech (搜索) received FDA approval for an updated irrigation flow rate on its VARIPULSE Platform (搜索), reflecting data-driven improvements based on real-world clinical experience.
The approval follows the company's milestone of surpassing 10,000 VARIPULSE procedures across nine countries and regions globally.
The platform has maintained a neurovascular adverse event rate of less than 0.5% based on internal customer reported data.
Johnson & Johnson MedTech (搜索) has received U.S. Food and Drug Administration (FDA) approval for an updated irrigation flow rate on its VARIPULSE Platform (搜索), marking a significant advancement in pulsed field ablation (搜索) (PFA) technology based on real-world clinical data.
The approval represents the company's commitment to continuous innovation in electrophysiology, incorporating feedback from clinical practice to enhance procedural performance and safety.
Real-World Experience Drives Innovation
"By learning from real-world experience and working closely with clinicians, we are continuously enhancing our technologies to improve patient care," said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, Johnson & Johnson MedTech (搜索). "This update to the VARIPULSE Platform (搜索) reflects our ongoing commitment to lead the evolution of PFA through meaningful, data-driven improvements that advance product performance and build procedural confidence."
The platform update follows extensive clinical experience, with Johnson & Johnson MedTech (搜索) achieving a significant milestone of surpassing 10,000 VARIPULSE procedures across multiple international markets, including the U.S., Europe, Canada, Japan, Hong Kong, China, Korea, Taiwan, and Australia.
Safety Profile Maintained
Throughout this extensive clinical experience, the VARIPULSE Platform (搜索) has demonstrated a favorable safety profile, maintaining a neurovascular adverse event rate of less than 0.5%. This rate is calculated from internal customer reported data and complaints, representing preliminary data pending publication rather than results from a prospective clinical investigation.
Advancing Pulsed Field Ablation Technology
The irrigation flow rate update represents part of Johnson & Johnson MedTech (搜索)'s broader strategy to advance PFA technology through continuous improvement based on clinical feedback. The VARIPULSE Platform (搜索) is part of the company's comprehensive electrophysiology portfolio, designed to address the evolving needs of cardiac electrophysiology procedures.
The approval underscores the importance of post-market surveillance and continuous improvement in medical device development, particularly in emerging technologies like pulsed field ablation (搜索) where real-world experience provides valuable insights for optimization.